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The risk of cardiovascular complication in a diabetes patient is similar to that in a nondiabetic patient with a history
of myocardial infarction. Although intensive control of glycemia achieved by conventional antidiabetic agents
decreases microvascular complications such as retinopathy and nephropathy, no marked effect has been reported
on macrovascular complications or all-cause mortality. Evidence from VADT, ACCORD, and ADVANCE would suggest
that glycemic control has little effect on macrovascular outcomes. Moreover, in the case of ACCORD, intensive
glycemic control may be associated with an increased risk of mortality. There is sufficient evidence that suggests
that postprandial hyperglycemia may be an independent risk factor for cardiovascular disease in diabetes patients.
However, there are no prospective clinical trials supporting the recommendation that lowering postprandial blood
glucose leads to lower risk of cardiovascular outcomes. Mitiglinide is a short-acting insulinotropic agent used in
type 2 diabetes treatment. It has a rapid stimulatory effect on insulin secretion and reduces postprandial plasma
glucose level in patients with type 2 diabetes. Because of its short action time, it is unlikely to exert adverse effects
related to hypoglycemia early in the morning and between meals. Mitiglinide reduces excess oxidative stress and
inflammation, plays a cardioprotective role, and improves postprandial metabolic disorders. Moreover, mitiglinide
add-on therapy with pioglitazone favorably affects the vascular endothelial function in type 2 diabetes patients.
These data suggest that mitiglinide plays a potentially beneficial role in the improvement of postprandial
hyperglycemia in type 2 diabetes patients and can be used to prevent cardiovascular diseases. Although the results
of long-term, randomized, placebo-controlled trials for determining the cardiovascular effects of mitiglinide on
clinical outcomes are awaited, this review is aimed at summarizing substantial insights into this topic.
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Endothelial dysfunction occurs in diabetes patients, es-
pecially in chronic hyperglycemic condition [1-3].
Noninvasive testing of endothelial function for cardio-
vascular risk stratification has been the “holy grail” of
Cardiology for some time [4]. Unfortunately, because of
technical difficulties, the measurement of shear stress-
induced flow-mediated dilatation (FMD) of the brachial
artery by arterial ultrasound was used to evaluate vascu-
lar endothelial function and is not yet commonly prac-
ticed in large-scale clinical trials [5,6]. Instead of FMD,
new techniques have recently been proposed as* Correspondence: myamaoka@med.kitasato-u.ac.jp
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reproduction in any medium, provided the orpotentially applicable screening tools for evaluating vas-
cular endothelial function in humans. A novel noninva-
sive vascular test by pulse amplitude tonometry (PAT)
before and after reactive hyperemia (RH) is particularly
noteworthy [7]. Measuring digital RH-PAT involves
quantifying arterial pulsatile volume at rest and during a
condition of increased shear stress that results in the re-
lease of nitric oxide (NO) [8]. At least 50% of RH is
dependent on endothelial NO production [9]. PAT is
performed before and after a 5-min ischemic stress, gen-
erating an RH-PAT index, which is normalized with re-
spect to the control arm [10]. According to a previous
clinical study, 94 patients without obstructive coronary
artery disease and with/without coronary microvascular
endothelial dysfunction were examined using RH-PAT;
the average RH-PAT index was lower in patients with
coronary endothelial dysfunction than in those withl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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1.78 ± 0.08; P< 0.001) [7].
Clinical studies using the PAT probe have suggested
altered endothelial function in children with cardiovas-
cular risk of type 1 diabetes [11]. Further, impaired RH-
PAT responses have been shown to be inversely related
to multiple risk factors, particularly diabetes, obesity,
high cholesterol concentrations, and smoking, in a group
of nearly 2000 subjects in the Framingham Third Gener-
ation Cohort study [8]. In a recent randomized con-
trolled trial (RCT) using the RH-PAT technique, 35
patients with obesity hypoventilation syndrome were
randomized to either the noninvasive ventilation (NIV)
group or the control group represented by lifestyle
counseling [12]. After 1 month of NIV treatment, sleep
and blood gas measurements had improved markedly
but the inflammatory, metabolic, and cardiovascular
markers were not affected. Accordingly, neither RH-PAT
nor arterial stiffness improved [12]. Probably, the
intervention and/or the study period may be insuffi-
cient to improve endothelial function and other bio-
markers. In our previous study, 4-week intervention
for increasing physical activity had significantly
improved endothelial function in high-risk patients
with cardiovascular disease [13].
Why does atherosclerosis progress in type 2
diabetes patients?
Type 2 diabetes (non-insulin-dependent diabetes) is an
important risk factor in atherosclerotic cardiovascular
disease [14,15]. It is a chronic disease, affecting 346 mil-
lion people worldwide [16]. In many cases, type 2 dia-
betes is preceded by a symptom-free period of impaired
glucose tolerance (IGT) and/or impaired fasting glucose
(IFG), which are characterized by chronic hyperglycemia
with prediabetic condition. Hyperglycemia plays a spe-
cific role in atherosclerosis progression in patients with
diabetes and IGT [17]. Needless to say, control of other
cardiovascular risk factors, such as blood pressure, dysli-
pidemia, and smoking, have a more significant impact
than glycemic control in patients with type 2 diabetes
[18].
Endothelial dysfunction is the initial step in atheroscler-
osis and occurs in patients with chronic hyperglycemia
[17,19-23]. In hyperglycemia patients, oral glucose loading
rapidly suppresses endothelial-dependent vasodilatation
through increase in the production of oxygen-derived free
radicals [24]. In patients with diabetes and IGT, hypergly-
cemia is usually associated with other coronary risk fac-
tors, such as dyslipidemia, hypertension, and obesity.
These factors are also known to cause endothelial dys-
function [25-27]. Atherosclerosis-induced coronary artery
disease is the main cause of morbidity and mortality in
diabetic patients [28].Endothelial dysfunction is a key component of athero-
sclerosis and contributes to the development of clinical
cardiovascular disease [29]. In the presence of vascular
risk factors, vascular endothelial cells undergo pheno-
typic changes resulting in decreased nitric oxide bio-
activity, thereby promoting vasoconstriction, vascular
inflammation, endothelial-mesenchymal transition, and
thrombosis [30-32]. Coronary risk factors are associated
with impaired vasomotor function, and individuals with
abnormal vasodilator function have increased cardiovas-
cular event rates [33]. Obesity and diabetes, along with
the associated dyslipidemia and insulin resistance, have
been linked to impaired vasodilator responses in humans
[34-37] and animal models [38-40].
What are the possible effects of antidiabetic
agents?
Fatal and nonfatal macrovascular events induced by type 2
diabetes are the main reasons for decreased life expect-
ancy; it is about 8 years shorter in a 40-year-old patient
newly diagnosed with diabetes than in the general popula-
tion [41]. The risk of a cardiovascular complication in a
diabetes patient is similar to that in a nondiabetic patient
with a history of myocardial infarction [42]. Intensive
control of glycemia with conventional antidiabetic agents
decreases microvascular complications such as retin-
opathy and nephropathy, but it has no marked effect
on macrovascular complications or all-cause mortality
[43,44].
Substantial evidence suggests that postprandial
hyperglycemia may be an independent risk factor for
cardiovascular disease in diabetes patients [42,45-48].
Hyperglycemia acutely increases the levels of circulat-
ing proinflammatory cytokines by an oxidative mech-
anism, and the effects are pronounced in subjects
with IGT and diabetes [49]. Excessive oxidative stress
caused by imbalance between free-radical production
and antioxidant response, followed by systemic vascu-
lar inflammation, is involved in the pathogenesis of
cardiovascular disease in diabetes patients [50-52].
Considerable epidemiological and clinical studies,
such as the Funagata study and the Diabetes Epi-
demiology Collaborative analysis of Diagnostic criteria
in Europe (DECODE) study, have established that
even a prediabetic state, including IGT, is strongly
associated with the occurrence of cardiovascular dis-
eases [45,53,54]. Postprandial acceleration of oxidative
stress and inflammation has been observed in patients
with type 2 diabetes [49,55-58]. The reduction in ca-
rotid intima-media thickness was associated with the
improvement of postprandial but not fasting hypergly-
cemia [59]. Therefore, treating postprandial hypergly-
cemia may have a positive effect on atherosclerosis
progression and cardiovascular diseases.
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vascular events by improving hyperglycemia in both pre-
prandial and postprandial conditions, which may inhibit
atherosclerosis progression caused by hyperglycemia-
induced oxygen-derived free radicals [60]. Postprandial
hyperglycemia is an important target to prevent cardiovas-
cular events [61]. Moreover, postprandial dysmetabolism
(hyperglycemia and hyperlipidemia) is associated with
increased inflammation, endothelial dysfunction, decreased
fibrinolysis, plaque instability, and cardiac events, even in
nondiabetic patients [62].
By targeting mainly postprandial hyperglycemia, glinide
drugs and alpha-glucosidase inhibitors (α-GI) favorably
affect several cardiovascular risk factors such as obesity,
dyslipidemia, hypertension, and high glycemic variability
with little or no risk of hypoglycemia. Improving postpran-
dial hyperglycemia by acarbose favorably affects endothelial
function and carotid intima-media thickening in humans
and improves cardiac interstitial fibrosis and hypertrophy of
cardiomyocytes in animal models [63].
When antidiabetic monotherapy is not sufficient to
achieve the desired therapeutic effect, other drugs, such
as metformin, sulfonylureas, glinides, α-GI, thiazolidine-
diones, glucagon-like peptide-1 receptor agonists, dipep-
tidyl peptidase-4 inhibitors, and insulin, can be added to
the treatment regimen [64,65].
Pioglitazone is an antidiabetic agent and agonist of per-
oxisome proliferator-activated receptor-γ (PPAR-γ); it
improves insulin resistance and is widely used in type 2 dia-
betes treatment to prevent cardiovascular disorders [66,67].
Compared to placebo, pioglitazone reduced the risk of con-
version of impaired glucose tolerance to type 2 diabetes by
72%, but it was associated with significant weight gain and
edema [68]. Bladder cancer episodes significantly increased
after pioglitazone administration in rodents and humans
[69], which may trigger the growth of bladder tumors by in-
creasing the local expression of vascular endothelial growth
factors [70]. Therefore, physicians tend to prefer a combin-
ation therapy with pioglitazone and other anti-diabetic
agent to high-dose pioglitazone monotherapy. One of the
best options may be mitiglinide add-on therapy with the
standard dose of pioglitazone, in which mitiglinide over-
comes the insufficiency of pioglitazone to improve post-
prandial hyperglycemia in type 2 diabetes patients.
Although the results of long-term, randomized,
placebo-controlled trials for determining cardiovascular
effects of antidiabetic agents in terms of clinical out-
comes are awaited, herein, we aimed to summarize sub-
stantial insights about mitiglinide.
Mitiglinide, an immediate short-acting
insulinotropic agent
Asian population is more insulin resistance than others
[71]. Asian patients with type 2 diabetes showed severalcharacteristic features such as high insulin resistance
with low BMI and relatively young age at diagnosis [72].
Mitiglinide, an insulinotropic sulfonylurea (SU) receptor
ligand, is a benzylsuccinic acid derivative developed in
Japan. It is an insulin secretagogue that acts on pancre-
atic β-cells, and unlike other SU agents, it has rapid ac-
tion and short action time [73-77]. Its preprandial
administration controls postprandial hyperglycemia and
improves overall glycemic control [78]. Because of its
short action time, it is unlikely to exert hypoglycemic
adverse effects early in the morning and between meals.
Therefore, mitiglinide may become a first choice drug
for the early stage of type 2 diabetes [79].
Mitiglinide exerts selective action on the ATP-
dependent K channel (KATP) channel (Kir6.2/SUR1) of
pancreatic β-cells and has stronger affinity to the chan-
nel than other insulinotropic SU receptor ligands,
namely, repaglinide and nateglinide [80]. In addition to
its glucose-lowering effect, mitiglinide inhibits postpran-
dial hypertriglyceridemia in OLETF (Otsuka Long-Evans
Tokushima Fatty) rats, which exhibit insulin resistance
and visceral fat accumulation and are considered as
aging diabetes models [81]. Mitiglinide also improves
postprandial hyperglycemia in type 2 diabetes patients
via both an insulin-mediated indirect effect on the liver




Compared to persistent hyperglycemia, intermittent
hyperglycemia, ie, glucose spikes, induces apoptosis of
vascular endothelial cells [83]. Mitiglinide shows rapid
stimulatory effect on insulin secretion and reduces post-
prandial plasma glucose levels in type 2 diabetes patients
[73-75]. In type 2 diabetes patients, mitiglinide improved
postprandial glucose levels, but it had no effect on
increased serum adiponectin levels or decreased urinary
albumin excretion [84].
Mitiglinide reduces the levels of circulating biomar-
kers of oxidative stress and inflammation caused by
postprandial hyperglycemia [85]. In a meal test in 40
diabetic patients, 10 mg mitiglinide administration
stimulated rapid insulin secretion, accompanied by
reduction of postprandial hyperglycemia [85]. The
study showed that controlling postprandial hypergly-
cemia with mitiglinide significantly improved the
levels of oxidative stress and inflammation markers
that are increased in the postprandial state in diabetic
patients [85].
Mitiglinide administration also decreased free fatty
acids (FFA) levels at 60 min after a meal tolerance test
in type 2 diabetes patients [86]. Mitiglinide significantly
lowered hemoglobin A1c (HbA1c) levels and increased
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cantly decreased urinary albumin levels after 12 months
[86]. These data suggest that mitiglinide certainly
improved postprandial hyperglycemia, which is crucial
to treating metabolic disorders, including insulin resist-
ance and dyslipidemia, in type 2 diabetes patients.
Mitiglinide has cardioprotective effects
The term meglitinide analogs was introduced in 1995 to
cover new molecules proposed as non-sulfonylurea insu-
linotropic agents that had structural analogy with megli-
tinide, such as repaglinide, nateglinide, and mitiglinide
[87]. Results of the STOP-NIDDM trial [61] suggest that
meglinide analogs (glinide drugs) may help protect type
2 diabetes patients against cardiovascular events [88]. If
mitiglinide could even partly regulate oxidative stress
and vascular inflammation, it could be used to prevent
cardiovascular diseases. Mitiglinide treatment signifi-
cantly reduced plasma nitrityrosine, malondialdehyde
(MDA), and oxidant LDL (oxLDL) levels [85]. Further-
more, mitiglinide administration preserved plasma total
radical-trapping antioxidant parameter (TRAP) com-
pared with placebo. Importantly, mitiglinide decreased
the levels of proinflammatory cytokines such as interleu-
kin (IL)-6, IL-18, and tumor necrosis factor (TNF)-α
[85]. Although the study only examined the effect of
acute administration of mitiglinide, it appears that redu-
cing postprandial oxidative stress and inflammation may
result in long-term effects of cardiovascular prevention
in diabetic patients.
Postprandial insulin secretion is considered to increase
cystatin C levels, which provide an accurate estimate of
renal function in diabetic patients. In 19 Japanese dia-
betes patients, 3-month mitiglinide monotherapy
increased cystatin C levels and had no effect on hs-CRP
levels [89]. Hence, there is very less evidence to judge
the controversy.
Although the use of SU agents in type 2 diabetes
patients has been quite common, increased risk of car-
diovascular complications and increased fatality rate
after myocardial infarction have been reported in these
patients [90]. Sulfonylurea receptors (SUR), which con-
stitute the KATP channel, have 3 subtypes with differing
distributions: SUR1 (present in pancreatic β cells),
SUR2A (cardiac myocytes), and SUR2B (vascular smooth
muscle cells) [91,92]. Hence, in vitro selectivity of the in-
sulin secretagogues may be important for the cardiovas-
cular outcome of diabetic patients with coronary artery
disease [91]. In isolated perfused rat hearts, mitiglinide
(selective blocker for SUR1) preserved the cardioprotec-
tive effect of ischemic preconditioning compared to glib-
enclamide (nonselective SUR blocker) [93]. In another
study on isolated perfused rat hearts, glibenclamide
induced a significant increase in left ventricular end-diastolic pressure and significantly decreased the left
ventricular systolic/developed pressure, and glimepiride
induced significant decrease in the left ventricular devel-
oped pressure [94]. However, mitiglinide had no effects
on canine isolated coronary arteries or perfused rat
hearts. Thus, mitiglinide may be safer than glibencla-
mide and glimepiride with regard to its cardiovascular
effects in diabetes patients.
Effect of mitiglinide on endothelial function
Evidence from previous studies suggests the importance
of the association between postprandial hyperglycemia
and endothelial dysfunction in diabetes patients. The
outcomes of 12-week interventions of 300 mg/day acar-
bose, 270 mg/day nateglinide, or no medication were
compared among 3 groups (10 subjects in each group)
of patients with new-onset type 2 diabetes [95]. Only
acarbose improved postprandial endothelial function, as
assessed by %FMD at 0 and 120 min after a cookie test.
The effect of mitiglinide with pioglitazone on endothe-
lial function remains largely unexplored. To investigate
whether mitiglinide could improve endothelial function,
we performed a pilot study on mitiglinide add-on ther-
apy with pioglitazone on type 2 diabetes patients who
were insufficiently controlled with pioglitazone mono-
therapy. In 8 patients with type 2 diabetes mitiglinide
was administered as add-on therapy with 10 mg/day pio-
glitazone for 12 weeks. Endothelial function was mea-
sured with the RH-PAT (Itamar) technique in all
patients before and after the intervention [96,97]. Miti-
glinide add-on therapy significantly improved the RH-
PAT index from 1.6 ± 0.3 to 2.1 ± 0.5 (P= 0.0373) in dia-
betes patients with pioglitazone monotherapy (Figure 1).
Significant reduction of HbA1c (Japan Diabetes Society
[JDS]) levels from 6.4% ± 0.3% to 6.1% ± 0.4% (P= 0.0062)
was also observed without any other modification of life-
style or other drug administrations; however, there was
no reduction in triglyceride level, LDL cholesterol level,
body weight, or waist circumference. In type 2 diabetes
patients, combination therapy with mitiglinide and pio-
glitazone resulted in marked improvements in HbA1c
levels and endothelial function. In 16 patients with type
2 diabetes treated with 30 mg/day mitiglinide, levels of
plasma glucose, FFA, and urinary albumin excretion
were significantly decreased [86]. One of the mechan-
isms may be the reduction of circulating levels of FFA
by mitiglinide administration.
Effect of mitiglinide in randomized clinical trials
Although there has been no large-scale RCT on mitigli-
nide monotherapy or mitiglinide add-on therapy with
other antidiabetic drugs thus far, several RCTs for miti-
glinide therapy have been reported. In this review, we













Figure 1 Effect of mitiglinide add-on therapy on endothelial
function. Reactive hyperemia-peripheral arterial tonometry (RH-PAT)
index was measured for evaluating vascular endothelial function in
type 2 diabetes patients before and after the 12-week mitiglinide
add-on therapy.
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treatment can be assessed in future RCTs.
Several RCTs for mitiglinide monotherapy have been
reported. A multicenter, double-blind, randomized study
comparing mitiglinide with nateglinide in 291 Chinese
type 2 diabetes patients reported that 10 to 20 mg miti-
glinide 3 times daily exerted blood glucose control simi-
lar to 120 mg nateglinide 3 times daily [98].
Recently, an RCT of nateglinide, but not mitiglinide,
was reported from Japan. The diabetes and diffuse
coronary narrowing (DIANA) study is a prospective,
randomized, open-label multicenter trial [99]. JapaneseFigure 2 The effects of mitiglinide on endothelial function and preve
endothelial dysfunction and the subsequent atherosclerosis progression. FFpatients (n = 302) with coronary artery disease and IGT/
diabetes were randomly assigned to lifestyle intervention
only, voglibose, or nateglinide groups and their 1-year
coronary atherosclerotic changes were evaluated using
quantitative coronary arteriography. Although coronary
atherosclerotic changes were similar for voglibose and
nateglinide, an improvement in glycemic status after
1 year was associated with decreased atheroma progres-
sion, regardless of the treatment [99]. These data suggest
that improving postprandial hyperglycemia by lifestyle
modification, α-GI, or glinide drugs can prevent coron-
ary artery progression.
There are 2 RCTs of mitiglinide add-on treatment with
pioglitazone. In a 16-week, multicenter, randomized,
double blind, parallel-group study, mitiglinide adminis-
tration with pioglitazone monotherapy improved gly-
cemic control in 381 Japanese patients with type 2
diabetes [100]. HbA1c level at final evaluation was
7.43%± 0.97% in the pioglitazone monotherapy group
and 6.84%± 0.7in the mitiglinide 10 mg group [100]. In
type 2 diabetic patients, the combination therapy for
1 year improved HbA1c, fasting plasma glucose, and
postprandial plasma glucose levels [101].
How can mitiglinide be used to prevent
cardiovascular disease?
The management of high-risk patients with diabetes
includes not only diet and exercise but also a combination
of antihyperglycemic treatment with lipid-lowering, anti-
hypertensive, and antiplatelet therapy [60]. Numerous
agents with different mechanisms of action and differentnting cardiovascular disease. Multiple risk factors induce vascular
A, free fatty acids; oxLDL, oxidized low-density lipoprotein.
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improving glycemic control in patients with diabetes.
How do we select an appropriate combination of drugs
for antidiabetic therapy?
In case of advanced diabetes, combination therapy with
mitiglinide and insulin glargine, which has a 24-h time-
action profile with no pronounced peak [102,103], may be
a useful regimen to lower postprandial hyperglycemia be-
fore switching to high-dose of SUs or intensive insulin
therapy using insulin injections [104].
Furthermore, 10 mg of mitiglinide once a day at
lunchtime to twice daily injections of premixed insulin
are effective for type 2 diabetes treatment.
Especially for obese patients, the combination of cal-
orie restriction and mitiglinide administration lowered
the visceral fat area and body weight, whereas glimepir-
ide with restricted diet did not significantly reduce vis-
ceral fat area or body weight [105]. These findings
suggest that combined use of mitiglinide with calorie re-
striction is warranted in patients with obesity and/or
metabolic syndrome, and that short-acting oral hypergly-
cemic agents and exogenous short-acting insulin are use-
ful for those attempting to undergo lifestyle modification
[105].
The therapeutic options for patients with type 2 diabetes
and chronic kidney disease (CKD) are limited because
decreased glomerular filtration rate results in the accumu-
lation of certain drugs and/or their metabolites [106].
With careful monitoring of hypoglycemia, mitiglinide can
be safely used for diabetic CKD patients on hemodialysis
(HD) [107]. Moreover, combination therapy of mitiglinide
and voglibose may have the potential for treating diabetes
patients on HD [108]. In these cases, mitiglinide adminis-
tration should be initiated at a lower dose by monitoring
glycemic control. In non-HD CKD patients, repeated ask-
ing about hypoglycemic symptoms and adverse events
may be most important and useful to monitor the pres-
ence of hypoglycaemia [109].
The above findings indicate that in type 2 diabetes
patients at high risk of coronary artery disease, combin-
ation therapy with agents that improve vascular endo-
thelial function, such as mitiglinide and pioglitazone, is a
promising therapeutic strategy for total risk management
of cardiovascular disease prevention (Figure 2).
Conclusions
In conclusion, we reviewed the effects of mitiglinide on
postprandial hyperglycemia and vascular endothelial
function in type 2 diabetes patients. The results of long-
term RCTs for the ultimate determination of the cardio-
vascular effects of mitiglinide in terms of clinical outcomes
are awaited; however, the improvement of postprandial
hyperglycemia may be crucial to prevent atherosclerosis
progression and cardiovascular events.Abbreviations
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